WebApr 27, 2024 · Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20. April 27, 2024, 2:00 PM UTC. … WebJan 4, 2024 · CLN-081 is an orally available, irreversible EGFR inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells …
FDA Grants BTD to Novel EGFR Inhibitor for Locally Advanced or ...
WebDec 28, 2024 · - Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties WebJan 4, 2024 · The FDA has granted breakthrough therapy designation to CLN-081 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer … katia basic merino tweed
Marcia Horn@Exon20Group’s Tweets - Twitter
WebJun 7, 2024 · CLN-081 (Cullinan) Her2 and EGFR are related, an indeed EGFR is sometimes called Her1, but they do represent distinct driver mutations. One small molecule believed to work only with EGFR exon 20 insertion, and not with Her2 exon 20 mutants (or indeed EGFR wild-type NSCLC), is Cullinan’s CLN-081, said to be built on a unique … WebJan 4, 2024 · Shares of Cullinan Oncology Inc. shot up 15.2% in premarket trading Tuesday, after the biopharmaceutical company said its CLN-081 was granted … WebJan 4, 2024 · Cullinan Oncology’s CLN-081 today received a Breakthrough Therapy Designation from the FDA for the treatment of locally advanced or metastatic non–small … layout addwidget 顺序